Equities analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce $930,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Esperion Therapeutics’ earnings, with the highest sales estimate coming in at $1.00 million and the lowest estimate coming in at $900,000.00. The firm is expected to issue its next quarterly earnings report on Thursday, November 7th.

On average, analysts expect that Esperion Therapeutics will report full-year sales of $147.95 million for the current fiscal year, with estimates ranging from $146.40 million to $149.00 million. For the next year, analysts anticipate that the firm will report sales of $171.26 million, with estimates ranging from $115.34 million to $207.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($2.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.86) by ($0.15). The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.05 million. During the same period in the previous year, the business posted ($1.71) EPS. The firm’s revenue for the quarter was up 9720.0% compared to the same quarter last year.

Several equities research analysts have recently weighed in on ESPR shares. Cowen reiterated a “buy” rating and set a $80.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, July 18th. ValuEngine cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Northland Securities reiterated a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. Goldman Sachs Group cut shares of Esperion Therapeutics from a “neutral” rating to a “sell” rating and set a $50.00 price objective for the company. in a research report on Wednesday, May 29th. Finally, BidaskClub cut shares of Esperion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 31st. Three research analysts have rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Esperion Therapeutics has an average rating of “Hold” and an average target price of $74.00.

Shares of ESPR traded down $0.18 during trading hours on Wednesday, hitting $36.56. 279,136 shares of the stock were exchanged, compared to its average volume of 435,372. Esperion Therapeutics has a fifty-two week low of $33.13 and a fifty-two week high of $60.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.65 and a quick ratio of 5.65. The business has a 50-day moving average of $37.78 and a 200-day moving average of $44.26. The firm has a market capitalization of $998.52 million, a P/E ratio of -4.85 and a beta of 1.71.

In related news, CEO Timothy M. Mayleben purchased 5,000 shares of Esperion Therapeutics stock in a transaction on Friday, June 28th. The stock was acquired at an average cost of $46.00 per share, for a total transaction of $230,000.00. Following the completion of the acquisition, the chief executive officer now owns 66,163 shares of the company’s stock, valued at approximately $3,043,498. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Target N. V. Biotech purchased 50,000 shares of Esperion Therapeutics stock in a transaction on Tuesday, July 23rd. The stock was bought at an average price of $42.65 per share, with a total value of $2,132,500.00. Following the completion of the acquisition, the insider now directly owns 3,572,964 shares of the company’s stock, valued at approximately $152,386,914.60. The disclosure for this purchase can be found here. Insiders acquired 147,500 shares of company stock valued at $5,521,825 over the last 90 days. Corporate insiders own 7.70% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Natixis grew its holdings in Esperion Therapeutics by 72.9% in the second quarter. Natixis now owns 21,563 shares of the biopharmaceutical company’s stock worth $1,003,000 after purchasing an additional 9,095 shares during the period. Royal Bank of Canada grew its holdings in Esperion Therapeutics by 38.1% in the second quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 811 shares during the period. Verition Fund Management LLC acquired a new stake in Esperion Therapeutics in the second quarter worth $225,000. ClariVest Asset Management LLC acquired a new stake in Esperion Therapeutics in the second quarter worth $4,139,000. Finally, Bamco Inc. NY grew its holdings in Esperion Therapeutics by 2.7% in the second quarter. Bamco Inc. NY now owns 188,500 shares of the biopharmaceutical company’s stock worth $8,769,000 after purchasing an additional 5,000 shares during the period.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Further Reading: What is a recession?

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.